Role of melatonine on proliferation and cellular migration in line of human medulloblastoma

• Grant number: 14/23830-1
• Support Opportunities: Scholarships in Brazil - Scientific Initiation
• Start date: February 01, 2015
• End date: January 31, 2017
• Field of knowledge: Biological Sciences - Physiology - General Physiology
• Principal Investigator: Pedro Augusto Carlos Magno Fernandes
• Grantee: Luiza Henriques Ostrowski
• Host Institution: Instituto de Biociências (IB). Universidade de São Paulo (USP). São Paulo , SP, Brazil

Abstract

Medulloblastoma is the most common tumor in children, and to be highly aggressive and invasive, is classified as grade IV by the World Health Organization and responsible for a large proportion of infant mortality from tumors. Conventional therapies for treatment are responsible for damaging the brain tissue in children's development and often cause sequelae. Studies have reported a greater sensitivity of tumor type in relation to the pathway of the nuclear transcription factor kB (NF-kB), since the same inhibition causes a decrease in proliferation of medulloblastoma cell line. Melatonin is a hormone produced by the pineal gland during the night and extrapineais sources in different physiological contexts. This hormone has several effects on the migration of brain tumors such as gliomas. Furthermore, melatonin is associated with modulation of inflammatory processes, being capable of inhibiting the nuclear translocation of NF-kB in many cell types. To date no data exist on the effects of melatonin on the aggressiveness of medulloblastomas literature. Thus, in this project the DAOY medulloblastoma line will be used to test the hypothesis that melatonin is able to cause a decrease in proliferation and migration of these cells.

Scientific publications

(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)

KINKER, G. S.; OSTROWSKI, L. H.; RIBEIRO, P. A. C.; CHANOCH, R.; MUXEL, S. M.; TIROSH, I.; SPADONI, G.; RIVARA, S.; MARTINS, V. R.; SANTOS, T. G.; et al. MT1 and MT2 melatonin receptors play opposite roles in brain cancer progression. JOURNAL OF MOLECULAR MEDICINE-JMM, v. 99, n. 2, JAN 2021. (14/23830-1, 14/27287-0, 13/13691-1, 17/24287-8, 14/50943-1, 15/23348-8)